Meet The Professors 2004 VOL 3, ISSUE 2

You are here: Home: Meet The Professors Vol. 3 Issue 2 2005: Case 6: Select publications

Bear HD et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: Results of NSABP B-27. San Antonio Breast Cancer Symposium 2004;Abstract 26.

Eliason JF, Megyeri A. Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets 2004;5(4):383-8. Abstract

Smith I et al. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial. Presentation. San Antonio Breast Cancer Symposium 2003;Abstract 1.

Smith IC et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002;20(6):1456-66. Abstract

Table of Contents

Home

Editor's Note:
Til death do us part

CASE 1: A 36-year-old woman with a family history of breast cancer and a poorly differentiated, node-negative IDC of the breast who wishes to retain her fertility (from the practice of Dr Richard S Zelkowitz)

- Select publications

Case 2: A 48-year-old woman with an ER/PR-negative, HER2-positive invasive ductal carcinoma with 11/16 positive nodes who developed CNS and bone metastases three years after local and adjuvant systemic therapy (from the practice of Dr Leonard J Seigel)

- Select publications

Case 3: A 73-year-old woman with ER/PR-positive, node-positive breast cancer who was switched to exemestane after three years of adjuvant tamoxifen (from the practice of Dr Arnold S Blaustein)

- Select publications

Case 4: A woman in her late forties diagnosed with a small, node-negative breast tumor who developed a sternal metastasis after two and one half years of tamoxifen with a shift in tumor phenotype from the primary lesion (from the practice of Dr Lowell L Hart)

- Select publications

Case 5: A 67-year-old woman a large ER/PR-positive, HER2-negative infiltrating ductal carcinoma with two positive lymph nodes (from the practice of Dr Lawrence A Tepper)

- Select publications

Case 6: A 41-year-old woman with an ER/PR-positive, HER2-negative breast tumor who had significant residual disease after AC and docetaxel neoadjuvant therapy (from the practice of Dr Michael S Wertheim)

- Select publications

Case 7: A 72-year-old woman with high-risk, ER/PR-positive breast cancer who refuses treatment with AIs after experiencing uncommon side effects and who subsequently develops a painful metastatic skin nodule and bone metastases (from the practice of Dr David M Dresdner)

- Select publications

CME Information

Faculty and Affiliations

Editor's Office

Home · Contact Us

Terms of Use and General Disclaimer
Copyright © 2005 Research To Practice. All Rights Reserved